Cargando…

Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease with poor prognosis. Pirfenidone and nintedanib are anti-fibrotic drugs used for patients with IPF. These drugs reduce the rate of decline in forced vital capacity (FVC). Serum surfactant protein (SP)-A, SP-D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshikawa, Takumi, Otsuka, Mitsuo, Chiba, Hirofumi, Ikeda, Kimiyuki, Mori, Yuki, Umeda, Yasuaki, Nishikiori, Hirotaka, Kuronuma, Koji, Takahashi, Hiroki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995128/ https://www.ncbi.nlm.nih.gov/pubmed/32005219 http://dx.doi.org/10.1186/s12890-020-1060-y

Ejemplares similares

Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
por: Yoshikawa, Takumi, et al.
Publicado: (2020)

Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage
por: Shioya, Makoto, et al.
Publicado: (2018)

Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis
por: Nishikiori, Hirotaka, et al.
Publicado: (2014)

Autoimmune Pulmonary Alveolar Proteinosis Diagnosed after Exposure to a Fire Extinguisher Containing Silica Powder
por: Yorozuya, Takafumi, et al.
Publicado: (2019)

Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis
por: Takahashi, Youhei, et al.
Publicado: (2018)

Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan
por: Ikeda, Kimiyuki, et al.
Publicado: (2020)

Deep-learning algorithm to detect fibrosing interstitial lung disease on chest radiographs
por: Nishikiori, Hirotaka, et al.
Publicado: (2023)

Insufficient serum L-ficolin is associated with disease presence and extent of pulmonary Mycobacterium avium complex disease
por: Kobayashi, Tomofumi, et al.
Publicado: (2019)

Pneumocystis jirovecii Pneumonia Associated with COVID-19 in Patients with Interstitial Pneumonia
por: Takahashi, Tomoyuki, et al.
Publicado: (2022)

CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases–associated interstitial lung disease and interstitial pneumonia with autoimmune features
por: Kameda, Masami, et al.
Publicado: (2020)

Programmed Death-Ligand 1-Positive Squamous Cell Carcinoma Spontaneously Regressed after Percutaneous Needle Biopsy
por: Sasahara, Masayuki, et al.
Publicado: (2023)

A case of tracheal pleomorphic adenoma misdiagnosed as asthma
por: Takahashi, Mamoru, et al.
Publicado: (2019)

Aberrant populations of circulating T follicular helper cells and regulatory B cells underlying idiopathic pulmonary fibrosis
por: Asai, Yuichiro, et al.
Publicado: (2019)

Simultaneous Pseudoprogression and an Immune-related Adverse Event of Pulmonary Pleomorphic Carcinoma after Combined Therapy with Cytotoxic Anticancer Agents and Immune Checkpoint Inhibitor
por: Murao, Koutaro, et al.
Publicado: (2022)

Daily physical activity affects exercise capacity in patients with idiopathic pulmonary fibrosis
por: Morino, Akira, et al.
Publicado: (2017)

The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D
por: Samukawa, Takuya, et al.
Publicado: (2012)

Development of a new HISCL automated CXCL9 immunoassay
por: Hasegawa, Takehiro, et al.
Publicado: (2023)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment
por: Cilli, Aykut, et al.
Publicado: (2023)

Coronavirus Disease 2019 Vaccine-Induced Flare-Up of Severe Bronchial Asthma Previously Controlled With Dupilumab: A Case Report
por: Sumi, Toshiyuki, et al.
Publicado: (2023)

The Role of Pulmonary Surfactant Phospholipids in Fibrotic Lung Diseases
por: Tlatelpa-Romero, Beatriz, et al.
Publicado: (2022)

Systemic lymph node tuberculosis presenting with an aseptic psoas abscess caused by a paradoxical reaction after nine months of antituberculosis treatment: a case report
por: Yamada, Gen, et al.
Publicado: (2013)

Analysis of real-world data and a mouse model indicates that pirfenidone causes pellagra
por: Kuronuma, Koji, et al.
Publicado: (2022)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
por: Dempsey, Timothy M., et al.
Publicado: (2022)

Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
por: Astor, Todd L., et al.
Publicado: (2023)

B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents
por: Roman, Jesse, et al.
Publicado: (2021)

Factors affecting dyspnea after the 6-minute walk test in idiopathic pulmonary fibrosis patients presenting with exercise-induced hypoxemia
por: Morino, Akira, et al.
Publicado: (2017)

Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
por: Khor, Yet H., et al.
Publicado: (2020)

T Cells in Fibrosis and Fibrotic Diseases
por: Zhang, Mengjuan, et al.
Publicado: (2020)

Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
por: Hostettler, Katrin E, et al.
Publicado: (2014)

A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
por: Roach, Katy M., et al.
Publicado: (2018)

Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study
por: Wu, Wen-Jui, et al.
Publicado: (2022)

Acute eosinophilic pneumonia accompanied with COVID‐19: a case report
por: Murao, Koutaro, et al.
Publicado: (2020)

Protective effect of Bifidobacterium longum BB536 against nausea caused by pirfenidone in a mouse model of pellagra
por: KURONUMA, Koji, et al.
Publicado: (2023)

Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic interstitial pneumonias
por: Higo, Hisao, et al.
Publicado: (2022)

N‐glycosylation regulates MET processing and signaling
por: Saitou, Atsushi, et al.
Publicado: (2022)

Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
por: Takei, Reoto, et al.
Publicado: (2023)

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
por: De Biasi, Sara, et al.
Publicado: (2015)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Cluster phenotypes in a non-idiopathic pulmonary fibrosis fibrotic interstitial lung diseases cohort in Singapore
por: Kam, Michelle Li Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tlbe9mg6pucbg5p7kvrfks1e9r